European Commission Imposes Hefty Fine on Firm for Blocking Rival MS Drug Developer
Last week, the European Commission announced that it had imposed a half-a-billion dollar fine on Teva, a multinational pharmaceutical firm based in Israel. The company, which specializes in generic drugs, is said to have artificially extended patent protection for its multiple sclerosis drug known as Copaxone. The drug has glatiramer acetate as its active ingredient. In a statement, the commission argued that the company’s actions may have hindered considerable savings by nations across Europe given that other versions of the medication may be cheaper than Copaxone. In total, Teva is expected to pay a 462.6 million euro fine. This is…